Last reviewed · How we verify
pravastatin, rosuvastatin
Both pravastatin and rosuvastatin inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.
Both pravastatin and rosuvastatin inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of myocardial infarction and stroke risk.
At a glance
| Generic name | pravastatin, rosuvastatin |
|---|---|
| Sponsor | Yokohama City University Medical Center |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These are statins that competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By reducing hepatic cholesterol production, they lower circulating LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. This reduces atherosclerotic plaque formation and cardiovascular event risk.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary and secondary prevention of cardiovascular disease
- Reduction of myocardial infarction and stroke risk
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes (ALT/AST)
- Headache
- Rhabdomyolysis (rare)
- Nausea
Key clinical trials
- Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy (PHASE1, PHASE2)
- LATAM LOWERS LDL-C (PHASE4)
- Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial (PHASE4)
- A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (NA)
- Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study
- StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial (PHASE4)
- A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808) (PHASE3)
- Real World Evidence Study of Statin Use in Brazil
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pravastatin, rosuvastatin CI brief — competitive landscape report
- pravastatin, rosuvastatin updates RSS · CI watch RSS
- Yokohama City University Medical Center portfolio CI